Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MYOK

MyoKardia (MYOK) Stock Price, News & Analysis

MyoKardia logo

About MyoKardia Stock (NASDAQ:MYOK)

Advanced Chart

Key Stats

Today's Range
$224.91
$224.91
50-Day Range
$222.81
$224.91
52-Week Range
$42.65
$225.00
Volume
N/A
Average Volume
752,969 shs
Market Capitalization
$11.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Receive MYOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter.

MYOK Stock News Headlines

Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
See More Headlines

MYOK Stock Analysis - Frequently Asked Questions

MyoKardia, Inc. (NASDAQ:MYOK) posted its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.44) by $0.16.

Based on aggregate information from My MarketBeat watchlists, some other companies that MyoKardia investors own include NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/05/2020
Today
4/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYOK
Fax
N/A
Employees
318
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-276,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.56 million
Price / Cash Flow
N/A
Book Value
$8.79 per share
Price / Book
25.59

Miscellaneous

Free Float
N/A
Market Cap
$11.99 billion
Optionable
Optionable
Beta
1.84
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MYOK) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners